Drug Profile
Respiratory syncytial virus vaccine - AlphaVax/Novartis
Alternative Names: RSV vaccine - AlphaVax; RSV-F vaccine - AlphaVaxLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator AlphaVax
- Class Respiratory syncytial virus vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (Parenteral)
- 24 Jul 2020 RSV vaccine is still in preclinical development for Respiratory-syncytial-virus-infections (Prevention) in USA (AlphaVax pipeline, July 2020)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (Parenteral)